Nektar Therapeutics (NASDAQ:NKTR) finished Wednesday with a subtraction of -$0.09 to close at $0.91, a downside of -8.94 percent. An average of 45,815,980 shares of common stock have been traded in the last five days. There was a gain of $0.3870 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 12,813,860 shares traded, while the 50-day average volume stands at 7,959,638.
NKTR stock has increased by 57.43% in the last month. The company shares reached their 1-month lowest point of $0.5051 on 07/26/23. With the stock rallying to its 52-week high on 02/07/23, shares of the company touched a low of $0.51 and a high of $5.18 in 52 weeks. It has reached a new high 15 times so far this year and lost -59.71% or -$1.3494 in price. In spite of this, the price is down -82.42% from the 52-week high.
Insider Transactions
NKTR stock investors should be aware that Nektar Therapeutics (NKTR) stock had its last reported insider trading activity 57 days ago on Jun 14. In this transaction, the insider spent $17,100. President & CEO, ROBIN HOWARD W, disposed of 20,361 shares at a price of $0.72 on May 16. The insider now owns more than $14,660 worth of shares. Prior to that, Chief R&D Officer Zalevsky Jonathan went on to Sale 9,791 shares at $0.72 each on May 16. An amount of $7,050 was transacted.
Valuation Metrics
Nektar Therapeutics (NKTR) stock’s beta is 0.87. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.88, the price-to-book (PB) ratio at 0.71.
Financial Health
The quick ratio of Nektar Therapeutics for the three months ended March 30 was 7.90, and the current ratio was 8.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending March 30. Nektar Therapeutics’s EBITDA margin for the year ending March 30 is -247.72%. Its gross profit as reported stood at $70.42 million compared to revenue of $92.06 million.
Earnings Surprise
For the three-month period that ended March 30, Nektar Therapeutics had $379.87 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$137.02 million in the quarter, while revenues of -$59.69 million were grew 34.03%. The analyst consensus anticipated Nektar Therapeutics’s latest quarter earnings to come in at -$0.25 per share, but it turned out to be -$0.73, a -192.00% surprise. For the quarter, EBITDA amounted to -$59.04 million. At the end of the quarter ending March 30, Nektar Therapeutics’s stock balance sheet showed total liabilities of 320.88 million. Shareholders own equity worth $189.24 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Nektar Therapeutics (NKTR) price momentum. RSI 9-day as of the close on 09 August was 73.46%, suggesting the stock is Overbought, with historical volatility in this time frame at 330.81%.
As of today, NKTR’s price is $0.7959 +73.91% or $0.3870 from its 5-day moving average. NKTR is currently trading +58.92% higher than its 20-day SMA and -18.70% lower than its 100-day SMA. However, the stock’s current price level is +44.04% above the SMA50 and -72.82% below the SMA200.
The stochastic %K and %D were 76.72% and 62.96%, respectively, and the average true range (ATR) was 0.1095. With the 14-day stochastic at 65.95% and the average true range at 0.0851, the RSI (14) stands at 71.39%. The stock has reached 0.2986 on the 9-day MACD Oscillator while the 14-day reading was at 0.3519.
Analyst Ratings
Jefferies upgraded Nektar Therapeutics (NASDAQ: NKTR) to a a Hold rating in its most recent analyst report. Previously, the stock was rated as an Underperform. The consensus rating for Nektar Therapeutics (NKTR) among analysts is Hold. According to current brokerage recommendations, 1 brokerage firm advise that investors sell NKTR, while 6 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
What is NKTR’s price target for the next 12 months?
Analysts predict a range of price targets between $0.60 and $6.00, with a median target of $1.75. Taking a look at these predictions, the average price target given by analysts for Nektar Therapeutics (NKTR) stock is $2.35.
